Evotec SE (EVO)

NMS – Real vaqt narxi. Valyuta: USD

2.19

+0.09 (4.29%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

2.19

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:55 PM EDT

06.08.2026

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programs Evotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical need HAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets.

03.08.2026

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

03.08.2026

Evotec SE (EVO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evotec SE (EVO)

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Search stocks

Evotec SE (EVO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evotec SE (EVO)

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Videolar

No Data

Press-relizlar

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168